Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study

Trial Profile

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Acronyms REMETY
  • Most Recent Events

    • 12 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top